Analysts at B. Riley dropped their Q2 2025 earnings per share estimates for Denali Therapeutics in a research note issued to investors on Wednesday, March 5th. B. Riley analyst M. Mamtani now ...

Morgan Stanley analyst Sean Laaman assumed coverage of Denali Therapeutics (DNLI) with an Overweight rating and a price target of $33, down ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Denali Therapeutics (DNLI – Research Report), ...

Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug.

2seventy bio Inc (TSVT) is expected to report $-0.20 for 4Q. 908 Devices Inc (MASS) is expected to report $-0.39 for 4Q. ATN International Inc (ATNI) is expected to report $-0.24 for 4Q. Aclaris ...

Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Denali Therapeutics in a ...

We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we ...

Denali Therapeutics DNLI reported a fourth-quarter 2024 loss of 67 cents per share, narrower than the Zacks Consensus ...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and ...

Career advancement opportunities through education has become accessible to employees of national government agencies (NGA) based in Davao del Norte  as the Provincial Government  opened the Davao del ...

Vicki L. Sato, a director at Denali Therapeutics Inc. (NASDAQ:DNLI), recently executed a sale of common stock, according to a regulatory filing. On November 1, Sato sold 3,080... On Friday, Denali ...